{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:54:03Z","timestamp":1794966843580,"version":"4.9.1"},"reference-count":80,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In hemophilia, the unmet needs regarding adherence to prophylaxis and lack of effective long-term prophylaxis regimens, especially in patients with inhibitors, led to the production of emicizumab, the first non-factor medicine for subcutaneous administration in patients with severe and moderate hemophilia A with or without factor VIII inhibitors. This review describes the research steps behind the development of this game-changing medication as well as its success in the prophylaxis of bleeding episodes, as witnessed by the results of pivotal clinical trials but also by real-life use in the frame of a still expanding global market. We also discuss potential and actual adverse events and the nuances related to clinical use, such as laboratory monitoring, development of neutralizing antidrug antibodies, risk of thrombosis\/hypercoagulability and role in the management of surgical operations. The potential of emicizumab to prevent bleeding in other congenital and acquired coagulation disorders is also outlined.<\/jats:p>","DOI":"10.3324\/haematol.2022.282099","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T04:08:21Z","timestamp":1698898101000},"page":"1334-1347","source":"Crossref","is-referenced-by-count":37,"title":["Emicizumab: the hemophilia A game-changer"],"prefix":"10.3324","volume":"109","author":[{"given":"Pedro E.","family":"Alcedo Andrade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"60131","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020; 26(Suppl 6):1-158.","DOI":"10.1111\/hae.14046"},{"key":"60132","doi-asserted-by":"crossref","unstructured":"Leissinger C, Gringeri A, Antmen B. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011; 365(18):1684-1692.","DOI":"10.1056\/NEJMoa1104435"},{"key":"60133","doi-asserted-by":"crossref","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-544.","DOI":"10.1056\/NEJMoa067659"},{"key":"60134","doi-asserted-by":"crossref","unstructured":"Kitazawa T, Shima M. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIacofactor activity. Int J Hematol. 2020; 111(1):20-30.","DOI":"10.1007\/s12185-018-2545-9"},{"key":"60135","doi-asserted-by":"crossref","unstructured":"Muto A, Yoshihashi K, Takeda M. Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014; 12(2):206-213.","DOI":"10.1111\/jth.12474"},{"key":"60136","doi-asserted-by":"crossref","unstructured":"Muto A, Yoshihashi K, Takeda M. Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014; 124(20):3165-3171.","DOI":"10.1182\/blood-2014-07-585737"},{"key":"60137","doi-asserted-by":"crossref","unstructured":"Shima M, Hanabusa H, Taki M. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016; 374(21):2044-2053.","DOI":"10.1056\/NEJMoa1511769"},{"key":"60138","doi-asserted-by":"crossref","unstructured":"Shima M, Hanabusa H, Taki M. Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017; 1(22):1891-1899.","DOI":"10.1182\/bloodadvances.2017006684"},{"key":"60139","doi-asserted-by":"crossref","unstructured":"Uchida N, Sambe T, Yoneyama K. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016; 127(13):1633-1641.","DOI":"10.1182\/blood-2015-06-650226"},{"key":"60140","doi-asserted-by":"crossref","unstructured":"Yoneyama K, Schmitt C, Kotani N. A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A. Clin Pharmacokinet. 2018; 57(9):1123-1134.","DOI":"10.1007\/s40262-017-0616-3"},{"key":"60141","doi-asserted-by":"crossref","unstructured":"Gouw SC, van der Bom JG, Ljung R. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013; 368(3):231-239.","DOI":"10.1056\/NEJMoa1208024"},{"key":"60142","doi-asserted-by":"crossref","unstructured":"Peyvandi F, Mannucci PM, Garagiola I. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016; 374(21):2054-2064.","DOI":"10.1056\/NEJMoa1516437"},{"key":"60143","doi-asserted-by":"crossref","unstructured":"Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015; 21(3):310-319.","DOI":"10.1111\/hae.12621"},{"key":"60144","doi-asserted-by":"crossref","unstructured":"DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007; 13(Suppl 1):1-22.","DOI":"10.1111\/j.1365-2516.2007.01497.x"},{"key":"60145","doi-asserted-by":"crossref","unstructured":"Oldenburg J, Mahlangu JN, Kim B. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017; 377(9):809-818.","DOI":"10.1056\/NEJMoa1703068"},{"key":"60146","doi-asserted-by":"crossref","unstructured":"Young G, Liesner R, Chang T. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019; 134(24):2127-2138.","DOI":"10.1182\/blood.2019001869"},{"key":"60147","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018; 379(9):811-822.","DOI":"10.1056\/NEJMoa1803550"},{"key":"60148","doi-asserted-by":"crossref","unstructured":"Pipe SW, Shima M, Lehle M. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019; 6(6):e295-e305.","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"60149","doi-asserted-by":"crossref","unstructured":"Yang R, Wang S, Wang X. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemost. 2022; 6(2):e12670.","DOI":"10.1002\/rth2.12670"},{"key":"60150","doi-asserted-by":"crossref","unstructured":"Negrier C, Mahlangu J, Lehle M. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023; 10(3):e168-e177.","DOI":"10.1016\/S2352-3026(22)00377-5"},{"key":"60151","doi-asserted-by":"crossref","unstructured":"Pipe SW, Collins P, Dhalluin C. Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study. Blood. 2022; 140(Suppl 1):457-459.","DOI":"10.1182\/blood-2022-157264"},{"key":"60152","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022; 28(Suppl 4):103-110.","DOI":"10.1111\/hae.14524"},{"key":"60153","unstructured":"Buntz B. The 50 best-selling pharmaceuticals of 2022: COVID-19 vaccines poised to take a step back. 2023. Publisher Full Text|"},{"key":"60154","doi-asserted-by":"crossref","unstructured":"Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019; 119(7):1084-1093.","DOI":"10.1055\/s-0039-1688687"},{"key":"60155","doi-asserted-by":"crossref","unstructured":"Adamkewicz JI, Kiialainen A, Paz-Priel I. Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays. Int J Lab Hematol. 2020; 42(2):e71-e75.","DOI":"10.1111\/ijlh.13114"},{"key":"60156","doi-asserted-by":"crossref","unstructured":"Dargaud Y, Lienhart A, Janbain M. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018; 103(4):e181-e183.","DOI":"10.3324\/haematol.2017.185330"},{"key":"60157","doi-asserted-by":"crossref","unstructured":"Kizilocak H, Yukhtman CL, Marquez-Casas E. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019; 10:2040620719860025.","DOI":"10.1177\/2040620719860025"},{"key":"60158","doi-asserted-by":"crossref","unstructured":"Lenting PJ. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv. 2020; 4(9):2111-2118.","DOI":"10.1182\/bloodadvances.2019000849"},{"key":"60159","doi-asserted-by":"crossref","unstructured":"Hartmann R, Feenstra T, Valentino L, Dockal M, Scheiflinger F. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018; 16(8):1580-1591.","DOI":"10.1111\/jth.14203"},{"key":"60160","doi-asserted-by":"crossref","unstructured":"Barg AA, Budnik I, Avishai E. Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring. Haemophilia. 2021; 27(3):383-391.","DOI":"10.1111\/hae.14318"},{"key":"60161","doi-asserted-by":"crossref","unstructured":"Kitazawa T, Igawa T, Sampei Z. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012; 18(10):1570-1574.","DOI":"10.1038\/nm.2942"},{"key":"60162","doi-asserted-by":"crossref","unstructured":"Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A. Thromb Haemost. 2020; 120(10):1357-1370.","DOI":"10.1055\/s-0040-1714279"},{"key":"60163","doi-asserted-by":"crossref","unstructured":"Howard M, McKinley D, Sanabria F, Ko RH, Nissen F. Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies. Blood. 2021; 138(Suppl 1):3186.","DOI":"10.1182\/blood-2021-146147"},{"key":"60164","doi-asserted-by":"crossref","unstructured":"Hassan E, Jonathan L, Jayashree M. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors. Haemophilia. 2021; 27(6):e698-e703.","DOI":"10.1111\/hae.14432"},{"key":"60165","doi-asserted-by":"crossref","unstructured":"Ebbert PT, Xavier F, Seaman CD, Ragni MV. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia. 2020; 26(1):41-46.","DOI":"10.1111\/hae.13877"},{"key":"60166","unstructured":"Buckner T, Daoud N, Croteau SE. ATHN 7: a natural history cohort study of the safety, effectiveness, and practice of treatment for people with hemophilia-demographics and preliminary results [abstract]. Res Pract Thromb Haemost. 2023. Publisher Full Text|"},{"key":"60167","doi-asserted-by":"crossref","unstructured":"Nissen F, Jiang Y, Hiew HJ. Real-world safety of emicizumab: interim analysis of the European Haemophilia Safety Surveillance (EUHASS) database. Blood. 2022; 140(Suppl 1):469-470.","DOI":"10.1182\/blood-2022-157528"},{"key":"60168","doi-asserted-by":"crossref","unstructured":"Levy-Mendelovich S, Brutman-Barazani T, Budnik I. Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab. J Clin Med. 2021; 10(19):4303.","DOI":"10.3390\/jcm10194303"},{"key":"60169","doi-asserted-by":"crossref","unstructured":"Misgav M, Brutman-Barazani T, Budnik I. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real-world data. Haemophilia. 2021; 27(2):253-260.","DOI":"10.1111\/hae.14261"},{"key":"60170","doi-asserted-by":"crossref","unstructured":"Callaghan MU, Negrier C, Paz-Priel I. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021; 137(16):2231-2242.","DOI":"10.1182\/blood.2020009217"},{"key":"60171","doi-asserted-by":"crossref","unstructured":"Kaneda M, Kawasaki R, Matsumoto N. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. J Thromb Haemost. 2021; 19(12):2938-2946.","DOI":"10.1111\/jth.15506"},{"key":"60172","doi-asserted-by":"crossref","unstructured":"Valsecchi C, Gobbi M, Beeg M. Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor. J Thromb Haemost. 2021; 19(3):711-718.","DOI":"10.1111\/jth.15226"},{"key":"60173","doi-asserted-by":"crossref","unstructured":"Shimonishi N, Nogami K, Ogiwara K. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII. Haemophilia. 2020; 26(3):e97-e105.","DOI":"10.1111\/hae.13961"},{"key":"60174","doi-asserted-by":"crossref","unstructured":"Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood. 2017; 130(23):2463-2468.","DOI":"10.1182\/blood-2017-08-801662"},{"key":"60175","doi-asserted-by":"crossref","unstructured":"Barg AA, Avishai E, Budnik I. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Pediatr Blood Cancer. 2019; 66(11):e27886.","DOI":"10.1002\/pbc.27886"},{"key":"60176","doi-asserted-by":"crossref","unstructured":"Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood. 2014; 124(23):3365-3372.","DOI":"10.1182\/blood-2014-05-577643"},{"key":"60177","doi-asserted-by":"crossref","unstructured":"Glonnegger H, Andresen F, Kapp F. Emicizumab in children: bleeding episodes and outcome before and after transition to emicizumab. BMC Pediatr. 2022; 22(1):487.","DOI":"10.1186\/s12887-022-03546-1"},{"key":"60178","doi-asserted-by":"crossref","unstructured":"Wieland I. Emicizumab for all pediatric patients with severe hemophilia A. Hamostaseologie. 2022; 42(2):104-115.","DOI":"10.1055\/a-1727-1384"},{"key":"60179","unstructured":"Santagostino E, Oldenburg J, Chang T. Surgical experience from four phase III studies (HAVEN 1-4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors abstract. 2023. Publisher Full Text|"},{"key":"60180","doi-asserted-by":"crossref","unstructured":"Castaman G, Windyga J, Alzahrani H. Surgical experience from the phase III STASEY trial of emicizumab prophylaxis in persons with hemophilia A with FVIII inhibitors: final analysis. Blood. 2021; 138(Suppl 1):344.","DOI":"10.1182\/blood-2021-145890"},{"key":"60181","doi-asserted-by":"crossref","unstructured":"Barg AA, Livnat T, Budnik I. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br J Haematol. 2020; 191(2):282-290.","DOI":"10.1111\/bjh.16964"},{"key":"60182","doi-asserted-by":"crossref","unstructured":"Castaman G, Linari S, Pieri L. Safe and successful surgical outcome in persons with hemophilia A with and without inhibitors treated with emicizumab: a large, single center, real-world experience. J Clin Med. 2023; 12(6):2317.","DOI":"10.3390\/jcm12062317"},{"key":"60183","doi-asserted-by":"crossref","unstructured":"Kruse-Jarres R, Kempton CL, Baudo F. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017; 92(7):695-705.","DOI":"10.1002\/ajh.24777"},{"key":"60184","doi-asserted-by":"crossref","unstructured":"Hansenne A, Hermans C. Emicizumab in acquired haemophilia A: about two clinical cases and literature review. Ther Adv Hematol. 2021; 12:20406207211038193.","DOI":"10.1177\/20406207211038193"},{"key":"60185","doi-asserted-by":"crossref","unstructured":"Knoebl P, Thaler J, Jilma P. Emicizumab for the treatment of acquired hemophilia A. Blood. 2021; 137(3):410-419.","DOI":"10.1182\/blood.2020006315"},{"key":"60186","unstructured":"Pezeshkpoor B, Sereda N, Berkemeier A. Neutralizing anti-emicizumab antibodies in a patient with acquired hemophilia A [abstract]. 2023. Publisher Full Text|"},{"key":"60187","doi-asserted-by":"crossref","unstructured":"Poston JN, Al-Banaa K, von Drygalski A. Emicizumab for the treatment of acquired hemophilia A: a multicenter US case series. Blood. 2021; 138(Suppl 1):496.","DOI":"10.1182\/blood-2021-148040"},{"key":"60188","doi-asserted-by":"crossref","unstructured":"Shima M, Amano K, Ogawa Y. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost. 2023; 21(3):534-545.","DOI":"10.1016\/j.jtha.2022.10.004"},{"key":"60189","doi-asserted-by":"crossref","unstructured":"Baud\u2019huin M, Duplomb L, Teletchea S. Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J Biol Chem. 2009; 284(46):31704-31713.","DOI":"10.1074\/jbc.M109.030312"},{"key":"60190","doi-asserted-by":"crossref","unstructured":"Samuelson Bannow B, Recht M, Negrier C. Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev. 2019; 35:43-50.","DOI":"10.1016\/j.blre.2019.03.002"},{"key":"60191","doi-asserted-by":"crossref","unstructured":"Kiialainen A, Niggli M, Kempton CL. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia. 2022; 28(6):1033-1043.","DOI":"10.1111\/hae.14642"},{"key":"60192","doi-asserted-by":"crossref","unstructured":"Yada K, Nogami K. Novel insights and new developments regarding coagulation revealed by studies of the anti-factor IXa (activated factor IX)\/factor X bispecific antibody, emicizumab. Arterioscler Thromb Vasc Biol. 2020; 40(5):1148-1154.","DOI":"10.1161\/ATVBAHA.120.312919"},{"key":"60193","unstructured":"Ogiwara K, Minami H, Nogami K. Anti-FIXa\/FX bispecific antibody (emicizumab) enhances plasma procoagulant activity in hemophilia B in the presence of very low level of factor IX. Res Pract Thromb Haemost: Res Pract Thromb Haemost. 2017; 1(Suppl 1):1438-1451."},{"key":"60194","unstructured":"Chau J, Sternberg A, Pishko A. Improved procoagulant activity of hemophilia B causing dysfunctional factor IX variants with factor VIII mimetics [abstract]. 2023. Publisher Full Text|"},{"key":"60195","doi-asserted-by":"crossref","unstructured":"Minami H, Nogami K, Yada K. Emicizumab, the bispecific antibody to factors IX\/IXa and X\/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro. J Thromb Haemost. 2019; 17(1):126-137.","DOI":"10.1111\/jth.14334"},{"key":"60196","doi-asserted-by":"crossref","unstructured":"Barg AA, Avishai E, Budnik I. The potential role of emicizumab prophylaxis in severe von Willebrand disease. Blood Cells Mol Dis. 2021; 87:102530.","DOI":"10.1016\/j.bcmd.2020.102530"},{"key":"60197","doi-asserted-by":"crossref","unstructured":"Barg AA, Kenet G, Livnat T. The potential role of emicizuamb prophylaxis in severe von Willebrand disease. Blood. 2020; 136(Suppl 1):20.","DOI":"10.1182\/blood-2020-138777"},{"key":"60198","doi-asserted-by":"crossref","unstructured":"Shanmukhaiah C, Jijina F, Kannan S. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): report of two cases and review of literature. Haemophilia. 2022; 28(2):286-291.","DOI":"10.1111\/hae.14491"},{"key":"60199","doi-asserted-by":"crossref","unstructured":"Thomas VM, Abou-Ismail MY, Lim MY. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature. Haemophilia. 2022; 28(1):4-17.","DOI":"10.1111\/hae.14450"},{"key":"60200","doi-asserted-by":"crossref","unstructured":"Yaoi H, Shida Y, Kitazawa T, Shima M, Nogami K. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions. Thromb Res. 2021; 198:7-16.","DOI":"10.1016\/j.thromres.2020.11.026"},{"key":"60201","doi-asserted-by":"crossref","unstructured":"Tripodi A, Chantarangkul V, Padovan L. Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. J Thromb Thrombolysis. 2020; 49(3):413-419.","DOI":"10.1007\/s11239-019-01993-9"},{"key":"60202","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Recombinant FVIII: the milestone of modern hemophilia treatment. Haematologica. 2023; 108(5):1201-1202.","DOI":"10.3324\/haematol.2023.282874"},{"key":"60203","doi-asserted-by":"crossref","unstructured":"Kjellev SL, \u00d8stergaard H, Greisen PJ. Mim8 - a next-generation FVIII mimetic bi-specific antibody - potently restores the hemostatic capacity in hemophilia A settings in vitro and in vivo. Blood. 2019; 134(Suppl_1):96.","DOI":"10.1182\/blood-2019-122817"},{"key":"60204","doi-asserted-by":"crossref","unstructured":"Yamaguchi K, Soeda T, Sato M. Pharmacology and pharmacokinetics of NXT007; emicizumab-based engineered FIXa\/ FX bispecific antibody with improved properties. Blood. 2020; 136(Suppl 1):19.","DOI":"10.1182\/blood-2020-138958"},{"key":"60205","doi-asserted-by":"crossref","unstructured":"Konkle BA, Shapiro AD, Quon DV. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med. 2020; 383(11):1018-1027.","DOI":"10.1056\/NEJMoa2002699"},{"key":"60206","doi-asserted-by":"crossref","unstructured":"von Drygalski A, Chowdary P, Kulkarni R. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023; 388(4):310-318.","DOI":"10.1056\/NEJMoa2209226"},{"key":"60207","doi-asserted-by":"crossref","unstructured":"Kenet G, Nolan B, Zulfikar B. A phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis [abstract]. 2023. Publisher Full Text|","DOI":"10.1097\/01.HS9.0000968124.64352.6e"},{"key":"60208","doi-asserted-by":"crossref","unstructured":"Shapiro AD, Angchaisuksiri P, Astermark J. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors. Blood Adv. 2022; 6(11):3422-3432.","DOI":"10.1182\/bloodadvances.2021006403"},{"key":"60209","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Lamas JL, Morales JC. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. Br J Haematol. 2023; 200(2):240-248.","DOI":"10.1111\/bjh.18495"},{"key":"60210","doi-asserted-by":"crossref","unstructured":"Mancuso ME, Callaghan MU, Kruse-Jarres R. Emicizumab prophylaxis in adolescent\/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study. Blood. 2017; 130(Suppl 1):1071.","DOI":"10.1182\/blood.V130.Suppl_1.89.89"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282099\/76276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282099\/76928","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11328\/76276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:11Z","timestamp":1794045911000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":80,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282099","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}